Design Considerations for Clinical Investigations of Osteoporosis

Robert P. Heaney

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

It is a commonplace of both clinical and investigative experience that things vary. No two individuals have quite the same bone size or density. Neither do bone mineral content (BMC) and remodeling activity respond to an intervention equally in every individual treated with a given agent. Moreover, the patients enrolled in an investigation of a new treatment for osteoporosis may differ, not only from one another, but from the larger group of patients the drug is intended to treat. Finally, those patients selected by their physicians to receive a particular treatment (e.g., hormone replacement therapy) may be different from those not selected. (Indeed, it would be hoped that the treatment choices by physicians and patients had a rational basis and were not decided by flips of a coin.).

Original languageEnglish
Title of host publicationOsteoporosis: Fourth Edition
PublisherElsevier Inc.
Pages1753-1776
Number of pages24
ISBN (Print)9780124158535
DOIs
StatePublished - Jun 2013

Fingerprint

Osteoporosis
Physicians
Numismatics
Hormone Replacement Therapy
Bone Density
Therapeutics
Bone and Bones
Pharmaceutical Preparations

All Science Journal Classification (ASJC) codes

  • Medicine(all)
  • Dentistry(all)

Cite this

Heaney, R. P. (2013). Design Considerations for Clinical Investigations of Osteoporosis. In Osteoporosis: Fourth Edition (pp. 1753-1776). Elsevier Inc.. https://doi.org/10.1016/B978-0-12-415853-5.00075-3

Design Considerations for Clinical Investigations of Osteoporosis. / Heaney, Robert P.

Osteoporosis: Fourth Edition. Elsevier Inc., 2013. p. 1753-1776.

Research output: Chapter in Book/Report/Conference proceedingChapter

Heaney, RP 2013, Design Considerations for Clinical Investigations of Osteoporosis. in Osteoporosis: Fourth Edition. Elsevier Inc., pp. 1753-1776. https://doi.org/10.1016/B978-0-12-415853-5.00075-3
Heaney RP. Design Considerations for Clinical Investigations of Osteoporosis. In Osteoporosis: Fourth Edition. Elsevier Inc. 2013. p. 1753-1776 https://doi.org/10.1016/B978-0-12-415853-5.00075-3
Heaney, Robert P. / Design Considerations for Clinical Investigations of Osteoporosis. Osteoporosis: Fourth Edition. Elsevier Inc., 2013. pp. 1753-1776
@inbook{87b6988c8a084eccbaf2cc77c16cfce9,
title = "Design Considerations for Clinical Investigations of Osteoporosis",
abstract = "It is a commonplace of both clinical and investigative experience that things vary. No two individuals have quite the same bone size or density. Neither do bone mineral content (BMC) and remodeling activity respond to an intervention equally in every individual treated with a given agent. Moreover, the patients enrolled in an investigation of a new treatment for osteoporosis may differ, not only from one another, but from the larger group of patients the drug is intended to treat. Finally, those patients selected by their physicians to receive a particular treatment (e.g., hormone replacement therapy) may be different from those not selected. (Indeed, it would be hoped that the treatment choices by physicians and patients had a rational basis and were not decided by flips of a coin.).",
author = "Heaney, {Robert P.}",
year = "2013",
month = "6",
doi = "10.1016/B978-0-12-415853-5.00075-3",
language = "English",
isbn = "9780124158535",
pages = "1753--1776",
booktitle = "Osteoporosis: Fourth Edition",
publisher = "Elsevier Inc.",
address = "United States",

}

TY - CHAP

T1 - Design Considerations for Clinical Investigations of Osteoporosis

AU - Heaney, Robert P.

PY - 2013/6

Y1 - 2013/6

N2 - It is a commonplace of both clinical and investigative experience that things vary. No two individuals have quite the same bone size or density. Neither do bone mineral content (BMC) and remodeling activity respond to an intervention equally in every individual treated with a given agent. Moreover, the patients enrolled in an investigation of a new treatment for osteoporosis may differ, not only from one another, but from the larger group of patients the drug is intended to treat. Finally, those patients selected by their physicians to receive a particular treatment (e.g., hormone replacement therapy) may be different from those not selected. (Indeed, it would be hoped that the treatment choices by physicians and patients had a rational basis and were not decided by flips of a coin.).

AB - It is a commonplace of both clinical and investigative experience that things vary. No two individuals have quite the same bone size or density. Neither do bone mineral content (BMC) and remodeling activity respond to an intervention equally in every individual treated with a given agent. Moreover, the patients enrolled in an investigation of a new treatment for osteoporosis may differ, not only from one another, but from the larger group of patients the drug is intended to treat. Finally, those patients selected by their physicians to receive a particular treatment (e.g., hormone replacement therapy) may be different from those not selected. (Indeed, it would be hoped that the treatment choices by physicians and patients had a rational basis and were not decided by flips of a coin.).

UR - http://www.scopus.com/inward/record.url?scp=84903098172&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84903098172&partnerID=8YFLogxK

U2 - 10.1016/B978-0-12-415853-5.00075-3

DO - 10.1016/B978-0-12-415853-5.00075-3

M3 - Chapter

SN - 9780124158535

SP - 1753

EP - 1776

BT - Osteoporosis: Fourth Edition

PB - Elsevier Inc.

ER -